Glenmark Pharmaceuticals ,Hikma enter join hands for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in US Medical Dialogues Bureau28 Feb 2020 9:12 AM GMTRyaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray...
Drugmaker Hikma cuts generics sales forecast a third time Ruby Khatun Khatun13 Nov 2017 4:00 AM GMTHikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for the third time.The Jordan-based firm, which makes...